Current Research Studies

Cancer - ADVL1513: Phase 1 Study of Entinostat, an Oral Histone Deacetylase Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

Condition or Therapy:

Recurrent solid tumors, refractory solid tumors

Category:

Cancer and Blood Disorders

What is the goal of this study?

This phase 1 trial studies the side effects and best dose of entinostat in treating pediatric patients with solid tumors that have come back or have not responded to treatment.

Who can join the study?

This study might be a good fit for children and young adults who:

Are between 21 months and 21 years old
Have recurrent or refractory solid tumors including CNS tumors or lymphoma, intrinsic brain stem tumors, optic pathway gliomas, pineal tumors, or elevations of cerebrospinal fluid (CSF) or serum tumors

What will happen if my child takes part in this study?

You can read more about this study on clinicaltrials.gov.

Who can I contact for more information?

To learn more, call 206-987-2106 or send us an email.

Study Location(s):

Seattle Children's Main Hospital Campus

Principal Investigator:

Looking for a Researcher?

Name: First Name Last Name
Area of Focus: Research Center:

©1995–2020 Seattle Children’s Hospital

4800 Sand Point Way NE,

Seattle,

WA

98105

206-987-2000

866-987-2000 (toll-free)

206-987-0391 (TTY)

Seattle Children’s complies with applicable federal and other civil rights laws and does not discriminate, exclude people or treat them differently based on race, color, religion (creed), sex, gender identity or expression, sexual orientation, national origin (ancestry), age, disability, or any other status protected by applicable federal, state or local law. Financial assistance for medically necessary services is based on family income and hospital resources and is provided to children under age 21 whose primary residence is in Washington, Alaska, Montana or Idaho.